Veracyte Inc Decipher® Prostate Test
Veracyte Inc (VCYT): New data that demonstrated the prognostic utility of its Decipher® Prostate genomic classifier in men with non-metastatic castration-resistant prostate cancer (nmCRPC) has been published online in This content is for paid subscribers.
Veracyte Inc: Exciting News About nmCRPC Published Online
Today’s Highlights June 14, 2021
Today’s Highlights
June 14, 2021
